Fujifilm moves into biologics with Merck buy

Tuesday, March 1, 2011 01:15 PM

Japan's Fujifilm is expanding its drug business in a deal to buy two of Merck's contract manufacturing facilities, according to Fierce Pharma.

Fujifilm is buying the Merck BioManufacturing Network and its biologics plants in North Carolina and Northeast England in an acquisition worth $490 million.  Merck will no longer focus on the contract biologics business, although the company will continue to perform some development and manufacturing services for Fujifilm. The deal will allow Fujifilm further expansion into medicine and pharma.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs